Zobrazeno 1 - 10
of 24
pro vyhledávání: '"David G J, Cucchi"'
Autor:
Tobias B. Polak, David G. J. Cucchi, Joost van Rosmalen, Carin A. Uyl-de Groot, Jonathan J. Darrow
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Patients with rare diseases often have limited or no options for approved treatments or participation in clinical trials. In such cases, expanded access (or “compassionate use”) provides a potential means of accessing unapproved investigational m
Externí odkaz:
https://doaj.org/article/8bbc06b9ca294fc1a327ee1a439bb5c2
Autor:
David G. J. Cucchi, Carolien Van Alphen, Sonja Zweegman, Bo Van Kuijk, Zinia J. Kwidama, Adil al Hinai, Alexander A. Henneman, Jaco C. Knol, Sander R. Piersma, Thang V. Pham, Connie R. Jimenez, Jacqueline Cloos, Jeroen J. W. M. Janssen
Publikováno v:
HemaSphere, Vol 5, Iss 7, p e606 (2021)
Externí odkaz:
https://doaj.org/article/a219996f1c814e4b922a7f69833bb632
Autor:
Tobias B. Polak, David G. J. Cucchi, Jasmin Schelhaas, Syed S. Ahmed, Naima Khoshnaw, Joost van Rosmalen, Carin A. Uyl-de Groot
Publikováno v:
Polak, T B, Cucchi, D G J, Schelhaas, J, Ahmed, S S, Khoshnaw, N, van Rosmalen, J & Uyl-de Groot, C A 2023, ' Results from Expanded Access Programs : A Review of Academic Literature ', Drugs, vol. 83, no. 9, pp. 795-805 . https://doi.org/10.1007/s40265-023-01879-4
Background: Although expanded access is an increasingly used pathway for patients to access investigational medicine, little is known on the magnitude and content of published scientific research collected via expanded access. Methods: We performed a
Publikováno v:
Blood, 139(12), 1920-1923. American Society of Hematology
Cucchi, D G J, Polak, T B, Ossenkoppele, G J, Rowe, J M & Estey, E H 2022, ' The predictive value of a positive phase 2 ASH abstract for peer-reviewed publication and progression to phase 3 ', Blood, vol. 139, no. 12, pp. 1920-1923 . https://doi.org/10.1182/blood.2021013988
Cucchi, D G J, Polak, T B, Ossenkoppele, G J, Rowe, J M & Estey, E H 2022, ' The predictive value of a positive phase 2 ASH abstract for peer-reviewed publication and progression to phase 3 ', Blood, vol. 139, no. 12, pp. 1920-1923 . https://doi.org/10.1182/blood.2021013988
Publikováno v:
Haematologica.
Not available.
Autor:
Carin A. Uyl-de Groot, David G. J. Cucchi, Jeroen Janssen, Jacqueline Cloos, Gert J. Ossenkoppele, Tobias B. Polak, Sonja Zweegman
Publikováno v:
Cucchi, D G J, Polak, T B, Ossenkoppele, G J, Uyl–De Groot, C A, Cloos, J, Zweegman, S & Janssen, J M W M 2021, ' Two decades of targeted therapies in acute myeloid leukemia ', Leukemia, vol. 35, no. 3, pp. 651-660 . https://doi.org/10.1038/s41375-021-01164-x
Precision medicine is gaining importance in the treatment of acute myeloid leukemia (AML). Objectively reviewing past and current knowledge aids guiding future research. Therefore, we provide a complete overview of all phase II and phase III trials i
Autor:
Arjan A. van de Loosdrecht, Carolien Duetz, Tobias B. Polak, Jeroen Janssen, Gert J. Ossenkoppele, Elihu H. Estey, David G. J. Cucchi
Publikováno v:
British Journal of Haematology, 196(2), 329-335. Wiley-Blackwell
Duetz, C, Cucchi, D G J, Polak, T B, Janssen, J J W M, Ossenkoppele, G J, Estey, E H & van de Loosdrecht, A A 2022, ' The wider perspective : twenty years of clinical trials in myelodysplastic syndromes ', British Journal of Haematology, vol. 196, no. 2, pp. 329-335 . https://doi.org/10.1111/bjh.17892, https://doi.org/10.1111/bjh.17892
British Journal of Haematology, 196(2), 329-335. Wiley-Blackwell Publishing Ltd
Duetz, C, Cucchi, D G J, Polak, T B, Janssen, J J W M, Ossenkoppele, G J, Estey, E H & van de Loosdrecht, A A 2022, ' The wider perspective : twenty years of clinical trials in myelodysplastic syndromes ', British Journal of Haematology, vol. 196, no. 2, pp. 329-335 . https://doi.org/10.1111/bjh.17892, https://doi.org/10.1111/bjh.17892
British Journal of Haematology, 196(2), 329-335. Wiley-Blackwell Publishing Ltd
Most patients with myelodysplastic syndromes (MDS) require therapeutic intervention. However, there are few approved treatments for MDS. To explore reasons, we searched clinicaltrials.gov and clinicaltrialsregister.eu for MDS trials from 2000 to 2020
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d085b97b104c327f7e6ae58a80d8be88
https://research.vumc.nl/en/publications/53d1dc92-b5fe-437a-a901-dd0730b9da4b
https://research.vumc.nl/en/publications/53d1dc92-b5fe-437a-a901-dd0730b9da4b
Autor:
François G. Kavelaars, Elvira Verhoef, Bianca Venniker-Punt, Peter J. M. Valk, Christian M. Vonk, Pauline A. Merle, Zinia J. Kwidama, Jacqueline Cloos, Patrycja L Gradowska, Jeroen Janssen, David G. J. Cucchi, Bob Löwenberg, Melissa Rijken
Publikováno v:
Cucchi, D G, Vonk, C M, Rijken, M, Kavelaars, F, Merle, P, Verhoef, E, Venniker-Punt, B, Kwidama, Z J, Gradowska, P, Löwenberg, B, Janssen, J J W M, Cloos, J & Valk, P J M 2021, ' DNA vs cDNA FLT3-ITD allelic ratio and length measurements in adult acute myeloid leukemia ', BLOOD ADVANCES, vol. 5, no. 21, pp. 4476-4479 . https://doi.org/10.1182/bloodadvances.2021004980
Blood Advances
Blood advances, 5(21), 4476-4479. American Society of Hematology
BLOOD ADVANCES, 5(21), 4476-4479. American Society of Hematology
Blood Advances
Blood advances, 5(21), 4476-4479. American Society of Hematology
BLOOD ADVANCES, 5(21), 4476-4479. American Society of Hematology
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28b787f38dc96d2345cc2e518086b31a
https://research.vumc.nl/en/publications/0a7b0550-67cd-4a96-a66d-a7a25142ae3d
https://research.vumc.nl/en/publications/0a7b0550-67cd-4a96-a66d-a7a25142ae3d
Autor:
Maarten R. Seefat, Kaz Groen, Stijn Dirven, David G. J. Cucchi, Sonja Zweegman, Hedwig M. Blommestein
Publikováno v:
Seefat, M R, Cucchi, D G J, Dirven, S, Groen, K, Zweegman, S & Blommestein, H M 2021, ' A systematic review of cost-effectiveness analyses of novel agents in the treatment of multiple myeloma ', Cancers, vol. 13, no. 22, 5606 . https://doi.org/10.3390/cancers13225606
Cancers
Cancers, Vol 13, Iss 5606, p 5606 (2021)
Cancers
Cancers, Vol 13, Iss 5606, p 5606 (2021)
Simple Summary New treatments in multiple myeloma are embraced by patients and physicians but are also associated with substantial higher costs. To ensure the affordability and accessibility of health care, an evaluation of the outcomes in relation t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::782186a31cc67188979d1e742be0f2cb
https://research.vumc.nl/en/publications/e2ff5a82-f768-4a33-82fd-ce2181da2950
https://research.vumc.nl/en/publications/e2ff5a82-f768-4a33-82fd-ce2181da2950
Publikováno v:
Polak, T B, Cucchi, D G J, van Rosmalen, J & Uyl-de Groot, C A 2022, ' The DRUG Access Protocol : access inequality and European harmonisation ', The Lancet Oncology, vol. 23, no. 5, pp. e202 . https://doi.org/10.1016/S1470-2045(22)00098-5
The Lancet Oncology, 23(5). Lancet Publishing Group
The Lancet Oncology, 23(5). Lancet Publishing Group